23 April 2009
BOXMEER (The Netherlands)
BOXMEER (the Netherlands), April 23, 2009 — Intervet/Schering-Plough Animal Health today announces the introduction in Europe of its PORCILIS PCV vaccine against porcine circovirus type 2 (PCV2) infection. The launch of this new subunit vaccine was celebrated this week with a dedicated scientific event near Lisbon (Portugal), attracting hundreds of veterinarians from all over Europe.
The new two-shot vaccine can be used for for the prevention and management of Porcine Circo Virus-associated Disease (PCVD), a major cause of economic loss in the pig sector. After having gained experience in Germany and Austria on a limited scale, the vaccine will now be introduced in the whole of Europe.
Major characteristics of PORCILIS PCV are that: (1) it contains the Cap-2 subunit antigen coded by ORF2 and therefore induces strong immunity against PCV2 infection; (2) it is combined with XSolve, an adjuvant offering immunity until the end of the fattening period; and (3) is able to break through medium-to-high levels of maternally-derived antibodies in piglets.
Infection with PCV2 is known to cause a variety of syndromes in pigs, together known as PCVD. Symptoms may include clinical signs such as weight loss or failure to grow, enlarged lymph nodes, difficulty in breathing, pale skin and jaundice. Field trials with PORCILIS PCV have demonstrated that vaccination of pigs at 3 weeks of age or older reduces the presence of virus load in the blood and lymphoid tissues and reduces weight loss associated with PCV2 infection during the fattening period.
For full prescribing information please read the Summary of Product Characteristics or contact your local Intervet/Schering-Plough Animal Health representative.
